Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Merck and Co Inc | 663 |
| 2 | Gilead Sciences Inc | 423 |
| 3 | Bristol Myers Squibb Co | 404 |
| 4 | Bayer AG | 358 |
| 5 | Roche Holding AG | 248 |
| 6 | Centre National de la Recherche Scientifique | 160 |
| 7 | The University of Texas System | 156 |
| 8 | Novartis AG | 150 |
| 9 | Vertex Pharmaceuticals Inc | 146 |
| 10 | Institut National de la Santé et de la Recherche Médicale | 135 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 16,957 |
| 2 | A61K | Medicinal preparations | 16,943 |
| 3 | C07D | Heterocyclic compounds | 5,588 |
| 4 | C07K | Peptides | 5,005 |
| 5 | C12N | Microorganisms, enzymes | 2,382 |
| 6 | G01N | Investigating / analysing materials | 1,690 |
| 7 | Y02A | Climate change adaptation | 1,438 |
| 8 | C07H | Sugars and derivatives | 1,028 |
| 9 | C12Q | Measuring/testing involving enzymes | 929 |
| 10 | C07F | Organometallic compounds | 798 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Polymer conjugates of ara-C and ara-C derivatives | 2002 | Icahn Enterprises LP | 56 |
| ANTITUMOR COMBINATIONS CONTAINING ANTIBODIES RECOGNIZING SPECIFICALLY CD38 AND CYTARABINE | 2010 | Sanofi SA | 49 |
| Preparing method for cytarabine | 2005 | 34 | |
| VOLASERTIB ALONE OR IN COMBINATION WITH CYTARABINE FOR TREATING ACUTE MYELOID LEUKEMIA | 2012 | C.H. Boehringer Sohn AG and Co KG | 30 |
| Polymer conjugates of ara-C and ara-C derivatives | 2003 | 26 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 258 |
| 2017 | 250 |
| 2018 | 285 |
| 2019 | 284 |
| 2020 | 303 |
| 2021 | 246 |
| 2022 | 236 |
| 2023 | 207 |
| 2024 | 187 |
| 2025 | 81 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Hagop M. Kantarjian | The University of Texas MD Anderson Cancer Center | 231 |
| 2 | Elihu H. Estey | The University of Texas MD Anderson Cancer Center | 132 |
| 3 | Jörge E. Cortes | The University of Texas MD Anderson Cancer Center | 122 |
| 4 | Farhad Ravandi | The University of Texas MD Anderson Cancer Center | 88 |
| 5 | Guillermo Garcia‐Manero | The University of Texas MD Anderson Cancer Center | 74 |
| 6 | Wolfgang Hiddemann | Ludwig-Maximilians-Universität München | 70 |
| 7 | Michael J. Keating | The University of Texas MD Anderson Cancer Center | 60 |
| 8 | William Plunkett | The University of Texas MD Anderson Cancer Center | 53 |
| 9 | Richard A. Larson | University of Chicago | 49 |
| 10 | Franco Mandelli | Sapienza University of Rome | 49 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia | 2003 | 3586 | Chronic Lymphocytic Leukemia Research |
| Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia | 2006 | 3498 | Chronic Lymphocytic Leukemia Research |
| Acute Myeloid Leukemia | 2015 | 3426 | Acute Myeloid Leukemia Research |
| Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation | 2017 | 2242 | Acute Myeloid Leukemia Research |
| Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro. | 1979 | 2067 | Mesenchymal stem cell research |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of cytarabine?
Which companies hold the most patents related to cytarabine?
What are the most prolific research authors in cytarabine studies?
What is the coverage of cytarabine in patent and scientific literature databases?
What therapeutic areas are most represented in cytarabine patent classifications?